Last viewed: ALLK


Prices are updated after-hours



nasdaq:ALLK Allakos Inc.

ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-7.8% 1m) (-34.0% 1y) (0.0% 2d) (1.7% 3d) (4.8% 7d) (-46.44% volume)
http://www.allakos.com
Sec Filling | Patents | 90 employees

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.

add to today's watch list email alert is off




antibody   monoclonal antibodies   t-cell   al002   treatment  

Press-releases


Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: -0.92% H: 0.0% C: 0.0%

atopic dermatitis expansion dermatitis
Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: 3.43% H: 2.45% C: 0.79%

ema
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting
Published: 2021-10-24 (Crawled : 20:20) - globenewswire.com
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: 3.43% H: 2.45% C: 0.79%

presentation disease
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: -0.12% H: 4.21% C: 2.01%

phase 2 clinical trials phase 2/3 phase 3 trial
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms
Published: 2021-05-24 (Crawled : 12:00) - globenewswire.com
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: 0.68% H: 0.45% C: -2.14%

test gastrointestinal
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
Published: 2021-03-30 (Crawled : 17:00) - globenewswire.com
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: 0.32% H: 1.55% C: -0.61%

presentation disease
RiverVest Venture Partners Closes $275 Million Life Sciences Fund
Published: 2021-03-23 (Crawled : 19:00) - biospace.com/
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: -1.08% H: 2.89% C: 0.73%
SPRB | $2.72 | twitter stocktwits trandingview |
Health Technology
| | O: -1.39% H: 0.9% C: -5.76%
MIRM | $14.51 | twitter stocktwits trandingview |
Health Technology
| | O: -0.3% H: 0.0% C: -7.49%

life science
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Published: 2021-03-01 (Crawled : 13:03) - globenewswire.com
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: 0.07% H: 4.76% C: -2.46%

financial results results
Allakos Appoints Natalie Holles to its Board of Directors
Published: 2020-12-22 (Crawled : 22:00) - globenewswire.com
ALLK | $77.6 | twitter stocktwits trandingview |
Health Technology
| | O: 0.67% H: 3.59% C: 3.08%


See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount
0001209191-21-054960 4 2021-09-07 Sell F 2346 210022
0001209191-21-054599 4 2021-09-03 Sell M 64148 88036
0001209191-21-054599 4 2021-09-03 Buy M 64148 212368


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying